DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application

被引：30

作者：

Antunes, Marina Venzon ^{[1
]}

Raymundo, Suziane ^{[1
]}

Wagner, Sandrine Comparsi ^{[1
,2
]}

Mattevi, Vanessa Sune ^{[2
]}

Vieira, Natalia ^{[2
]}

Leite, Renata ^{[2
]}

Reginato, Fabiola ^{[2
]}

Capra, Marcelo Zanella ^{[3
]}

Fogliatto, Laura ^{[4
]}

Linden, Rafael ^{[1
]}

机构：

[1] Univ Feevale, Inst Ciencias Saude, Novo Hamburgo, RS, Brazil

[2] Univ Fed Ciencias Saude Porto Alegre, Porto Alegre, RS, Brazil

[3] Grp Hosp Conceicao, Porto Alegre, RS, Brazil

[4] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

来源：

BIOANALYSIS | 2015年 / 7卷 / 16期

关键词：

DRIED BLOOD SPOT; BIOANALYTICAL METHODS; VALIDATION; ACID;

D O I：

10.4155/bio.15.101

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml(-1). DBS can increase access to IM therapeutic drug monitoring. Results: IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40 degrees C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1). Conclusion: IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.

引用

页码：2105 / 2117

页数：13

共 18 条

[1] Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods [J].

Almeida, AM ;

Castel-Branco, MM ;

Falcao, AC .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02) :215-222

[2] Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots-Development, validation and clinical application during breast cancer adjuvant therapy [J].

Antunes, Marina Venzon ;

Raymundo, Suziane ;

de Oliveira, Vanessa ;

Staudt, Dilana Elisabeth ;

Goessling, Gustavo ;

Peteffi, Giovana Piva ;

Biazus, Jorge Villanova ;

Cavalheiro, Jose Antonio ;

Tre-Hardy, Marie ;

Capron, Arnaud ;

Haufroid, Vincent ;

Wallemacq, Pierre ;

Schwartsmann, Gilberto ;

Linden, Rafael .

TALANTA, 2015, 132 :775-784

[3] Clinical evaluation of a dried blood spot method for determination of mycophenolic acid in renal transplant patients [J].

Arpini, Janaine ;

Antunes, Marina Venzon ;

Pacheco, Larissa Sgaria ;

Gnatta, Diego ;

Rodrigues, Mariana Ferraz ;

Keitel, Elizete ;

Linden, Rafael .

CLINICAL BIOCHEMISTRY, 2013, 46 (18) :1905-1908

[4] Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory [J].

Bouchet, Stephane ;

Titier, Karine ;

Moore, Nicholas ;

Lassalle, Regis ;

Ambrosino, Basmah ;

Poulette, Sylvie ;

Schuld, Peter ;

Belanger, Coralie ;

Mahon, Francois-Xavier ;

Molimard, Mathieu .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (06) :690-697

[5] Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer [J].

Capiau, Sara ;

Stove, Veronique V. ;

Lambert, Willy E. ;

Stove, Christophe P. .

ANALYTICAL CHEMISTRY, 2013, 85 (01) :404-410

[6] Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls [J].

Edelbroek, Peter M. ;

van der Heijden, Jacques ;

Stolk, Leo M. L. .

THERAPEUTIC DRUG MONITORING, 2009, 31 (03) :327-336

[7]

European Medicines Agency, 2022, Committee for Medicinal Products for Human Use, Guideline on Bioanalytical Method Validation

[8] Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry [J].

Kralj, Eva ;

Trontelj, Jurij ;

Pajic, Tadej ;

Kristl, Albin .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 903 :150-156

[9] In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia [J].

Kretz, O ;

Weiss, HM ;

Schumacher, MM ;

Gross, G .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (02) :212-216

[10] Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study [J].

Larson, Richard A. ;

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Riviere, Gilles J. ;

Krahnke, Tillmann ;

Gathmann, Insa ;

Wang, Yanfeng .

BLOOD, 2008, 111 (08) :4022-4028

← 1 2 →